Walleye Trading’s Vir Biotechnology VIR Stock Holding History

Walleye Trading’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,940	Closed	-$11.1K	–	4858
2025 Q3	$11.1K	Buy	+1,940	New	+$9.92K	﹤0.01%	4191
2023 Q3	–	Sell	-31,466	Closed	-$772K	–	5402
2023 Q2	$772K	Buy	+31,466	New	+$790K	﹤0.01%	2409
2022 Q1	–	Sell	-8,035	Closed	-$336K	–	5946
2021 Q4	$336K	Sell	8,035 -12,187	-60%	-$477K	﹤0.01%	3384
2021 Q3	$880K	Buy	+20,222	New	+$875K	﹤0.01%	2347

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $602M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Walleye Trading's VIR Position: Q4 2025 in Review

Walleye Trading sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 1,940 shares — an estimated $11.1K sold.

Walleye Trading first reported a position in VIR in Q3 2021 and held it in 4 quarters. The position peaked at $880K in Q3 2021. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

Walleye Trading reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
Walleye Trading sold 1,940 Vir Biotechnology shares in Q4 2025, an estimated $11.1K.
Walleye Trading first reported a position in Vir Biotechnology in Q3 2021 and held it in 4 quarters.
Walleye Trading's Vir Biotechnology position peaked at $880K in Q3 2021.
218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.